Introduction
The colony-stimulating factors (CSFs) are a group of cytokines that support the survival, proliferation, differentiation, and end cell function of myeloid cells (Metcalf, 1993) . For instance, granulocyte-CSF (G-CSF) enhances the production of neutrophils by inducing the proliferation and differentiation of its myeloid progenitor (Welte et al., 1985; Demetri and Griffin, 1991) . G-CSF also activates terminally differentiated neutrophils by enhancing antibody-dependent killing, phagocytic activity and priming the respiratory burst (Bober et al., 1995) . In agreement, G-CSF and G-CSF receptor deficient mice are severely neutropenic and susceptible to infections (Lieschke et al., 1994; Liu et al., 1996; Zhan et al., 1998; Battiwalla and McCarthy, 2009) . Therefore, G-CSF plays an essential role in steady-state neutrophil production and in acute/rapid granulopoiesis during infections (Zhan et al., 1998) .
The most important applicability of G-CSF in human therapy is related to granulopoiesis. The G-CSF treatment increases neutrophil counts in patients receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, patients receiving bone marrow transplant, patients undergoing peripheral blood progenitor cell collection and therapy, and patients with severe chronic neutropenia (Granulokine®, Filgrastim package insert; Dale et al., 1993; Battiwalla and McCarthy, 2009) .
Nevertheless, the G-CSF treatment induces some side effects. For instance, according to a retrospective analysis of 341 healthy donors, the main adverse events of G-CSF therapy (Granulokine®, Filgrastim package insert) are pain (84%), headache (54%), fatigue (31%) and nausea (13%) (Battiwalla and McCarthy, 2009) . In fact, G-CSF treatment induces bone, musculoskeletal and visceral pain in healthy volunteers and cancer patients (Granulokine®, Filgrastim package insert; Battiwalla and McCarthy, 2009) . Thus, pain is the main side effect of G-CSF therapy.
The main therapy used to control G-CSF-induced pain is the treatment with opioids such as morphine (Granulokine®, Filgrastim Pharmacology, Biochemistry and Behavior 98 (2011) Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / p h a r m b i o c h e m b e h package insert). However, prolonged treatment might induce dependence because of opioid receptors desensitization leading to increasing doses of morphine. Moreover, the side effects of morphine include nausea, constipation, somnolence/sedation, and respiratory failure (Devulder et al., 2009) . Evidence suggests spinal inhibition of pain processing as a successful strategy to reduce pain with reduced incidence of systemic side effect. The spinal inhibition of mytogen-activated protein (MAP) kinases p38, JNK (Jun Nterminal Kinase) and ERK (extracellular signal-regulated kinases), and PI 3 K (phosphatidilinositil 3-kinase) attenuate carrageenininduced peripheral hyperalgesia (Svensson et al., 2003; Choi et al., 2010; Fitzsimmons et al., 2010) , formalin-induced overt-pain (Pezet et al., 2008) and nerve lesion-induced neuropathic pain (Obata et al., 2004; Xu et al., 2007; Gao and Ji, 2010) . Thus, consistent data support that spinal inhibition of MAP kinases and PI 3 K reduce inflammatory and neuropathic pain.
In this sense, G-CSF also induces MAP kinases and PI 3 K activation dependent effects. G-CSF induces survival and/or proliferation via MAP kinases (p38, JNK and ERK) and/or PI 3 K activation dependent pathways Marshall, 1997, 1999; Dong and Larner, 2000; Hunter and Avalos, 2000; Kendrick et al., 2004) . Furthermore, anti-G-CSF antibody inhibits cancer-induced pain and spinal activation of ERK (Schweizerhof et al., 2009) . However, it is not known whether peripheral administration of G-CSF induces pain via spinal activation of p38, ERK and JNK, and/or PI 3 K. Therefore, we evaluated the spinal mechanisms involved in G-CSF injection-induced hyperalgesia in mice focusing on the participation of MAP kinases and PI 3 K.
Materials and methods

Animals
The experiments were performed on male Swiss mice (20-25 g, Universidade Estadual de Londrina, Londrina, PR, Brazil) housed in standard clear plastic cages (five per cage) with free access to food and water. All behavioral testing was performed between 9:00 am and 5:00 pm in a temperature-controlled room. Animals' care and handling procedures were in accordance with the International Association for Study of Pain (IASP) guidelines and with the approval of the Ethics Committee of the Universidade Estadual de Londrina. All efforts were made to minimize the number of animals used and their suffering. It is noteworthy that different experimenters prepared the solutions, made the administrations and performed the evaluation of overt pain-like behavior, mechanical and thermal hyperalgesia.
Electronic pressure-meter test for mice
Mechanical hyperalgesia was tested in mice as previously reported (Cunha et al., 2004) . Briefly, in a quiet room, mice were placed in acrylic cages (12 × 10 × 17 cm) with wire grid floors, 15-30 min before the start of testing. The test consisted of evoking a hind paw flexion reflex with a hand-held force transducer (electronic von Frey anesthesiometer; Insight, Ribeirão Preto, SP, Brazil) adapted with a 0.5 mm 2 contact area polypropylene tip. The investigator was trained to apply the tip perpendicularly to the central area of the hind paw with a gradual increase in pressure. The end point was characterized by the removal of the paw followed by clear flinching movements. After the paw withdrawal, the intensity of the pressure was recorded automatically. The value for the response was an average of three measurements. The animals were tested before and after treatment. The results are expressed by delta (Δ) withdrawal threshold (in g) calculated by subtracting the zero-time mean measurements from the mean measurements (indicated time points) after stimulus. The basal mechanical withdrawal threshold was 8.8 ± 0.1 g (mean ± SEM of 63 groups, 5 mice per group) before injection of stimulus or vehicle.
There was no difference of basal mechanical withdrawal thresholds between groups in the same experiment.
Overt pain-like behavior evaluation
Mice were placed in clear glass compartments and the number of paw flinches and time spent licking the paw were determined during 30 min after i.pl. injection of saline (25 μl), G-CSF (100 ng/paw) or formalin 1.5% (25 μl). Total counts were presented at 5 min intervals (Valerio et al., 2009 ).
Hot plate test
Mice were placed in a 10 cm-wide glass cylinder on a hot plate (Insight, Ribeirão Preto, SP, Brazil) maintained at 55°C. Two control latencies at least 10 min apart were determined for each mouse. The normal latency (reaction time) was 5-9 s. The latency was also evaluated 30 and 60 min after test compound administration. The reaction time was scored when the animal jumped or licked its paws. A maximum latency (cut-off) was set at 30 s to avoid tissue damage (Valerio et al., 2007) .
Intrathecal (i.t.) drug administration
The i.t. injections were performed under light halothane anesthesia (1-2%). The dorsal fur of each mouse was shaved, the spinal column was arched, and a 29-gauge needle was directly inserted into the subarachnoid space, between the L4 and L5 vertebrae (Mestre et al., 1994) . Correct i.t. positioning of the needle tip was confirmed by manifestation of a characteristic tail flick response. A 5 μl volume containing the test agent was slowly injected. Note that drugs delivered to the subarachnoidal space by i.t. injection can diffuse into the CSF, which bathes the spinal cord, the dorsal roots, and part of dorsal root ganglion (Funez et al., 2008 ).
Drugs
Drugs were obtained from the following sources: formalin (1.5%, 25 μl i.pl.) from Merk (Darmstadt, Germany), G-CSF (Granulokine, filgrastin, recombinant human G-CSF, 30-300 ng/paw) from Hoffmann La-Roche (Basileia, Swiss), morphine sulphate (2-12 μg/paw) from Cristalia (São Paulo, Brazil), naloxone hydrochloride (1 mg/Kg), PD98059 (1-10 μg/intrathecal [i.t.]), SB202190 (1-10 μg/i.t.), SP600125 (1-10 μg/i.t.), and wortmanin (0.3-3 μg/i.t.) were obtained from Sigma-Aldrich (St Louis, MO, USA). G-CSF, morphine, naloxone and formalin were dissolved in saline, and all other compounds were dissolved in 20% DMSO in saline.
Statistical analysis
Results are presented as means ± s.e.m. of measurements made on 5 animals in each group. Two-way analysis of variance (ANOVA) was used to compare the groups and doses at all times (curves) when the hyperalgesic responses were measured at different times after the stimulus injection. The analyzed factors were treatments, time and time versus treatment interaction. When there was a significant time versus treatment interaction, one-way ANOVA followed by Tukey's t-test was performed for each time. On the other hand, when the hyperalgesic responses were measured once after the stimulus injection, the differences between responses were evaluated by oneway ANOVA followed by Tukey's t-test. Additionally, comparative statistical analysis between two groups were done using t test. Statistical differences were considered to be significant at P b 0.05.
Results
Intraplantar (i.pl. -subcutaneous injection in the paw) injection of G-CSF induces mechanical hyperalgesia
Saline (25 μl) or G-CSF (30-300 ng/paw) was injected via i.pl. route, and mechanical hyperalgesia was evaluated after 1-48 h with electronic pressure-meter test (Fig. 1) . All doses of G-CSF tested induced significant mechanical hyperalgesia 1-7 h after administration, but only 100 and 300 ng of G-CSF induced significant hyperalgesia until 24 h, which decreased to control levels thereafter (48 h). One hundred and 300 ng of G-CSF induced significant hyperalgesia compared to the dose of 30 ng of G-CSF 7 and 24 h after stimulus, and 300 ng of G-CSF also induced significant hyperalgesia compared to 30 ng of G-CSF 5 h after stimulus. There was no statistical difference between 100 and 300 ng of G-CSF. Therefore, the G-CSF dose of 100 ng was chosen for the next experiments.
Morphine treatment inhibits G-CSF-induced hyperalgesia
Mice were treated with morphine (2, 6, and 12 μg/paw) or saline (20 μl) 4 h after i.pl. injection of G-CSF ( Fig. 2A) . Morphine dosedependently inhibited G-CSF-induced hyperalgesia at 5 h after stimulus injection ( Fig. 2A ). There was a tendency of reduction of G-CSF-induced hyperalgesia by 2 μg/paw of morphine, although not significant. On the other hand, the doses of 6 and 12 μg/paw of morphine significantly inhibited G-CSF-induced hyperalgesia, and their effect was also significantly different of the dose of 2 μg of morphine. Corroborating the specificity of morphine inhibition, the treatment with naloxone (1 mg/kg, i.p., 1 h before morphine) significantly prevented morphine (6 μg/paw) inhibition of G-CSFinduced hyperalgesia at 5 h (Fig. 2B) . The efficacy of 6 μg of morphine was local since had no effect on G-CSF-induced hyperalgesia when administrated in the contra-lateral paw (Fig. 2C) . The effect of morphine was evaluated at one time point because at the local doses tested, its effect lasts for approximately 1 h (Verri et al., 2006 (Verri et al., , 2008a .
G-CSF administration does not induce overt pain-like behavior or thermal hyperalgesia
Mice received i.pl. injection of saline (25 μl), G-CSF or formalin 1.5% (25 μl), and the number of paw flinching (Fig. 3A) and time spent licking (Fig. 3B) were evaluated during 30 min at 5 min intervals. G-CSF did not induce significant paw flinching or licking compared to saline group (Fig. 3A and B) . Additionally, other spontaneous nociceptive behaviors such as paw lifting or guarding were not observed (data not shown). On the other hand, the positive control Fig. 1 . Intraplantar injection of G-CSF induces mechanical hyperalgesia. Saline (25 μl) or G-CSF (30-300 ng/paw) was injected via intraplantar (i.pl.) route in mice and mechanical hyperalgesia was evaluated after 1-48 h with electronic pressure-meter test. Results are presented as means ± s.e.m. of 5 mice per group, and are representative of 2 separated experiments. * P b 0.05 compared to the saline group, and # P b 0.05 compared to the 30 ng/paw dose of G-CSF. (Two-way ANOVA, and one-way ANOVA followed by Tukey's t-test). The baseline mean values were: saline (8.3 ± 0.5), G-CSF 30 ng (8.5 ± 0.5), G-CSF 100 ng (8.8 ± 0.2), and G-CSF 300 ng (8.6 ± 0.4). , and ** P b 0.05 compared to G-CSF control group and the lower dose of morphine (2 μg/paw) (Oneway ANOVA followed by Tukey's t-test). The baseline mean values were: Panel Asaline (9.3 ± 0.5), G-CSF (8.6 ± 0.4), G-CSF + morphine 2 (8.5 ± 0.3), G-CSF + morphine 6 (9.2 ± 0.6), and G-CSF + morphine 12 (9.7 ± 0.5); Panel B -saline (9.3 ± 0.5), G-CSF (8.6 ± 0.4), G-CSF + morphine (9.1 ± 0.6), and G-CSF + morphine + naloxone (8.3 ± 0.5); Panel C -saline (8.2 ± 0.2), G-CSF (8.0 ± 0.5), G-CSF + morphine contralateral paw (8.1 ± 0.4).
group that received i.pl. injection of formalin presented significant paw flinching and licking compared to saline and G-CSF between 0-5, 15-20, 20-25 and 25-30 min (Fig. 3A and B) . The formalin-induced overt pain-like behavior was consistent with the model since presented two phases (Valerio et al., 2009) . In another set of experiments, the thermal nociceptive threshold was evaluated before and 5 h after i.pl. injection of saline (25 μl) or G-CSF with the hot plate test in mice (Fig. 3C) . G-CSF did not alter the thermal threshold of mice in the hot plate test.
Role of spinal ERK activation in G-CSF-induced hyperalgesia
Mice were treated intrathecally (i.t.) with the MEK1/2 inhibitor (prevents ERK1/2 activation) PD98059 (1-10 μg) or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF stimulus, and mechanical hyperalgesia was evaluated in the ipsilateral (Fig. 4A ) and contra-lateral (Fig. 4B) paws to G-CSF stimulus. These dose ranges and vehicle concentration were chosen based on previous studies (Zhuang et al., 2004 (Zhuang et al., , 2005 . The dose of 1 μg of PD98059 did not alter G-CSF-induced hyperalgesia (Fig. 4A) . On the other hand, the dose of 3 μg of PD98059 inhibited G-CSF-induced hyperalgesia 5 h after stimulus (Fig. 4A) . The dose of 10 μg of PD98059 significantly inhibited G-CSF hyperalgesia 1-7 h compared to vehicle i.t. + G-CSF, and 3-7 h compared to PD98059 1 μg i.t. + G-CSF groups (Fig. 4A) . The PD98059 i.t. treatment did not alter the mechanical hyperalgesia in the contra-lateral paw (Fig. 4B) .
Role of spinal JNK in G-CSF-induced hyperalgesia
Mice were treated i.t. with the JNK inhibitor SP600125 (1-10 μg) or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF stimulus, and mechanical hyperalgesia was evaluated in the ipsilateral (Fig. 5A ) and contra-lateral (Fig. 5B) paws to G-CSF stimulus. These dose ranges and vehicle concentration were chosen based on previous studies (Doya et al., 2005) . The dose of 1 μg of SP600125 did not alter G-CSF-induced hyperalgesia (Fig. 5A) . On the other hand, the dose of 3 μg of SP600125 inhibited G-CSF-induced hyperalgesia 3 and 5 h after stimulus injection (Fig. 5A) . The dose of 10 μg of SP600125 significantly inhibited G-CSF hyperalgesia compared to vehicle i.t. + G-CSF and SP600125 1 μg i.t. + G-CSF groups 3-7 h after stimulus injection (Fig. 5A) . The SP600125 i.t. treatment did not alter the mechanical hyperalgesia in the contra-lateral paw (Fig. 5B) .
Role of spinal p38 in G-CSF-induced hyperalgesia
Mice were treated i.t. with the p38 inhibitor SB202190 (1-10 μg) or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF stimulus, and mechanical hyperalgesia was evaluated in the ipsilateral (Fig. 6A ) and contra-lateral (Fig. 6B) paws to G-CSF stimulus. These dose ranges and vehicle concentration were chosen based on previous studies (Chen et al., 2009 ). The dose of 1 μg of SB202190 did alter G-CSF-induced hyperalgesia (Fig. 6A) . The dose of 3 μg of SB202190 inhibited G-CSF-induced hyperalgesia 5 h after stimulus (Fig. 6A) . The dose of 10 μg of SB202190 significantly inhibited G-CSF hyperalgesia 3-7 h compared to vehicle i.t. + G-CSG group, and 3-5 h compared to the dose of 1 μg of SB202190 (Fig. 6A) . The SB202190 i.t. treatment did not alter the mechanical hyperalgesia in the contra-lateral paw (Fig. 5B) .
Role of spinal PI 3 K in G-CSF-induced hyperalgesia
Mice were treated i.t. with the PI 3 K inhibitor wortmanin (0.3-3 μg) or vehicle (5 μl of 20% DMSO in saline) 30 min before i.pl. G-CSF stimulus, and mechanical hyperalgesia was evaluated in the ipsilateral (Fig. 7A ) and contra-lateral (Fig. 7B) paws to G-CSF stimulus. These dose ranges and vehicle concentration were chosen based on previous studies (Zhuang et al., 2004; Xu et al., 2007) . The dose of 0.3 μg of wortmanin did not alter G-CSF-induced hyperalgesia (Fig. 7A) . On the other hand, 1 and 3 μg of wortmanin significantly inhibited the hyperalgesia compared to vehicle i.t. + G-CSF and 0.3 μg i.t. + G-CSF groups 3-7 h after stimulus (Fig. 7A) . The dose of 3 μg of wortmanin inhibitory effect was also significant 1 h after stimulus compared to vehicle i.t. + G-CSF group (Fig. 7A) . The wortmanin i.t. treatment did not alter the mechanical hyperalgesia in the contra-lateral paw (Fig. 7B) . Five h after G-CSF stimulus there were significant differences between the doses of MAP kinases and PI 3 K inhibitors (Figs. 4A, 5A , 6A and 7A), which is also the peak of G-CSF-induced mechanical hyperalgesia (Fig. 1) . Therefore, this time point was used for the next experiment.
Combined Treatment with MAP kinases and PI 3 K inhibitors at doses that are ineffective as single treatment reduces G-CSF-induced hyperalgesia
Mice received single i.t. treatment with PD98059 (1 μg), SP600125 (1 μg), SB202190 (1 μg) or wortmanin (0.3 μg), or co-treatment with 1 μg of each MAP kinase inhibitors (PD98059, SP600125, SB202190) plus 0.3 μg of wortmanin in a single injection or vehicle (5 μl of 2% DMSO in saline) 30 min before G-CSF stimulus (Fig. 8) . G-CSF induced significant hyperalgesia 5 h after injection, which was unaffected by single treatment with PD98059, SP600125, SB202190 or wortmanin. On the other hand, the combination of those inhibitors at doses that were ineffective as single treatment significantly inhibited G-CSFinduced hyperalgesia (Fig. 8) .
Discussion
Granulocyte-colony stimulating factor (G-CSF) is a current therapy to increase neutrophil counts in peripheral blood of patients that underwent chemotherapy or radiotherapy for cancer treatment. The G-CSF therapy is well tolerated, but some side effects such as abdominal pain, bone pain and muscle-skeletal pain limit its applicability (Granulokine®, Filgrastim package insert; Battiwalla and McCarthy, 2009) . In the present study, it was demonstrated that G-CSF-induced mechanical hyperalgesia in mice depends on spinal activation of ERK, JNK, p38 and PI 3 K acting in synergy/sequence. Furthermore, the treatment with a dose of morphine with peripheral action also reduced G-CSF-induced hyperalgesia.
The intraplantar (subcutaneous plantar) injection of G-CSF induced hyperalgesia in mice at a dose equivalent to the recommended dose for humans of 5 μg/kg per day (Granulokine®, Filgrastim package insert). In humans, opioid treatment is a usual and efficient approach to inhibit G-CSF therapy-induced pain. In agreement, G-CSF-induced mechanical hyperalgesia in mice was reduced by morphine treatment, and this effect of morphine was inhibited by naloxone treatment. Thus, the response induced by G-CSF in mice seems to reflect what is seen in humans. It is important to note that patients may undergo G-CSF therapy for many weeks, and chronic use of opioids raise possible issues such as side effects, tolerance and addiction (Devulder et al., 2009) . In this sense, our study also suggests that it is worthy evaluating whether treatment with peripherally acting opioids is a conceivable approach to control G-CSF therapy-induced pain since morphine was effective at peripherally acting doses (e.g. ipsilateral but not contra-lateral treatment with morphine inhibited G-CSF hyperalgesia).
G-CSF can directly activate nociceptors since they express G-CSF receptor (G-CSFR) (Schweizerhof et al., 2009 ). However, it was not detected overt pain-like behavior by the hyperalgesic dose of 100 ng of G-CSF. This result is consistent with the effect of other cytokines that do not induced overt pain at hyperalgesic doses (Verri et al., 2008b) . G-CSF did not induce thermal hyperalgesia, which suggests disagreement with previous evidence (Schweizerhof et al., 2009) . Nevertheless, the use of different thermal tests involving different structure/mechanisms such as spinal (Hargreaves plantar test) versus supra-spinal (hot plate test) mechanisms (Le Bars et al., 2001 ) might explain these opposing results (Schweizerhof et al., 2009 and present data, respectively) . Therefore, G-CSF seems to activate spinal rather than supra-spinal mechanisms.
A common mechanism of inflammatory and neuropathic pain is the spinal activation of MAP kinases (ERK, JNK and p38) and PI 3 K (Svensson et al., 2003; Ji and Strichartz, 2004; Obata et al., 2004; Xu et al., 2007; Pezet et al., 2008; Choi et al., 2010; Fitzsimmons et al., 2010; Gao and Ji, 2010) . The activation of spinal MAP kinases and PI 3 K contribute to hyperalgesia by modulating ion channels, increasing the production of cytokines and other mediators and their receptors, and therefore, inducing the sensitization of nociceptors (Ji & Strichartz, 2004; Gao and Ji, 2010) . Interestingly, G-CSF also activates those kinases in other systems Marshall, 1997, 1999; Dong and Larner, 2000; Hunter and Avalos, 2000; Kendrick et al., 2004) . In agreement, inhibition of p38, ERK, JNK, and PI 3 K diminished G-CSF-induced hyperalgesia in a dose-dependent manner. Importantly, none of the intrathecal treatments with kinase inhibitors altered the mechanical hyperalgesia in the contra-lateral paw to G-CSF stimulus, indicating that PD98059, SB600125, SB202190 and wortmanin do not alter the basal mechanical threshold of normal tissue. Furthermore, the higher doses of p38, ERK, JNK, and PI 3 K inhibitors abolished G-CSF-induced hyperalgesia, which could be explained by a sequential or synergic role of spinal p38, ERK, JNK, and PI 3 K in G-CSF-induced hyperalgesia. In fact, the combined treatment with MAP kinases and PI 3 K inhibitors, at doses that are ineffective as single treatment, significantly reduced G-CSF hyperalgesia, therefore, indicating that these pathways act in sequence/synergy. Indicating a sequential pathway and the interaction of PI 3 K and MAP kinases, PI 3 K activates ERK in primary sensory neurons inducing heat hyperalgesia (Zhuang et al., 2004) , and PI 3 K activates p38 inducing cellular chemotaxis (Shahabuddin et al., 2006) . MAP kinases present a different interaction among them compared to PI 3 K/MAP kinases relationship since they can act in a co-dependent manner to activate transcription factors such as activating protein-1 (AP-1) as known for JNK and ERK (Kim and Iwao, 2003) . On the other hand, p38, ERK and JNK do not activate each other. Corroborating, ERK and p38 inhibitors do not affect G-CSF-induced JNK activation in a model of cell proliferation (Rausch and Marshall, 1997) . Thus, the combined treatment with MAP kinases and PI 3 K inhibitors could allow reduced doses of such inhibitors (1 μg of each MAP kinase inhibitor plus 0.3 μg of PI 3 K inhibitor) compared to single drug treatment (10 μg of a single MAP kinase inhibitor or 1-3 μg of PI 3 K inhibitor).
In addition to the present data, it was recently demonstrated the endogenous role of G-CSF in a mice model of bone cancer pain (Schweizerhof et al., 2009 ). The injection of pancreatic adenocarcinoma induces an increase of G-CSF production in the paw skin concomitantly with expression of G-CSFR by sensory dorsal root ganglion (DRG) neurons suggesting possible direct activation of nociceptors by G-CSF (Schweizerhof et al., 2009) . Furthermore, the treatment with anti-G-CSFR antibodies reduces tumor-induced mechanical hyperalgesia, demonstrating the G-CSF endogenous role in this model of cancer pain (Schweizerhof et al., 2009 ). G-CSF induces ERK activation in dorsal root ganglion neurons in vitro in a PI 3 K and MEK inhibitors (LY294002 and PD98059, respectively) sensitive manner, suggesting that G-CSF-induced ERK phosphorilation depends on prior PI 3 K activation (Schweizerhof et al., 2009 ). This result supports our hypothesis described above in which MAP kinases and PI 3 K pathways are interconnected and sequentially/synergistically mediate G-CSF hyperalgesia. Corroborating a role for G-CSF-triggered mechanisms in tumor-induced hyperalgesia, PD98059 treatment also inhibits carcinoma-induced hyperalgesia (Schweizerhof et al., 2009 ). Thus, Schweizerhof et al. (2009) demonstrated that endogenous G-CSF mediates tumor-induced hyperalgesia in a PI 3 K/ERK-dependent pathway. Nevertheless, it was not addressed whether the hyperalgesia induced by G-CSF administration could be diminished by MAP kinases or PI 3 K inhibitors, which is an experimental condition that could shed light in the pain mechanisms triggered by G-CSF therapy as demonstrated herein.
The present study confirmed that G-CSF induces mechanical hyperalgesia, and advanced by demonstrating an in vivo role of spinal MAP kinases (ERK, JNK and p38) and PI 3 K in G-CSF-induced mechanical hyperalgesia in mice.
